New atypical antipsychotic medications

Journal of Psychiatric Research

Volumn 32, Issue 3-4, 1998, Pages 215-228

  Jibson, Michael D ^a   Tandon, Rajiv ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

ARTICLE; COGNITION; COGNITIVE DEFECT; DRUG BLOOD LEVEL; DRUG EFFICACY; DYSPHORIA; EXTRAPYRAMIDAL SYNDROME; HUMAN; MOTOR DYSFUNCTION; NEGATIVE SYNDROME; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSIS; RECURRENCE RISK; SCHIZOPHRENIA; SYMPTOMATOLOGY;

EID: 0032072886     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3956(98)00023-5     Document Type: Article

References (80)

1. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998;18:63-101.
2. Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. New England Journal of Medicine 1991;324:746-754.
3. Beasley Jr. CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123.
4. Beasley Jr. CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996;124:159-167.
5. Beasley Jr. CM, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, Blin O, Beuzen JN. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. European Neuropsychopharmacology 1997;7:125-137.
6. Bench CJ, Lammertsma AA, Grasby PM, Dolan RJ, Warrington SJ, Boyce M, Gunn KP, Brannick LY, Frackowiak RS. The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography. Psychopharmacology 1996;124:141-147.
7. Bilder RM. Neurocognitive impairment in schizophrenia and how it affects treatment options. Canadian Journal of Psychiatry 1997;42:255-264.
8. Bilder RM, Lipschutz-Broch L, Reiter G, Geisler SH, Mayerhoff DI, Lieberman JA. Intellectual deficits in first-episode schizophrenia: evidence for progressive deterioration. Schizophrenia Bulletin 1992;18:437-448.
9. U.S. Seroquel Study Group, Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. Journal of Clinical Pharmacology 1996;16:158-169.
10. Brecher, M. Long-term safety of risperidone: results of seven 1-year trials (abstract). Scientific proceedings of the annual meeting of American College of Clinical Pharmacy, Nashville, Tennessee, August 4-7, 1996.
11. Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Archives of General Psychiatry 1991;48:239-246.
12. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter Jr. WT. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. American Journal of Psychiatry 1994;151:20-26.
13. Busatto GF, Kerwin RW. Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia. Journal of Psychopharmacology 1997;11:3-12.
14. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96.
15. Carpernter WT, Buchanan RW. Domains of psychopathology relevant to the study of etiology and treatment of schizophrenia. In: Schultz SC and Tamminga CT, editors. Schizophrenia: a scientific focus. New York: Oxford University Press, 1989.
16. Casey DE. Motor and mental aspects of EPS. International Clinical Psychopharmacology 1995;10:105-114.
17. Chatterjee A, Chakos M, Koreen A, Geisler S, Sheitman B, Woerner M, Kane JM, Alvir J, Lieberman JA. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. American Journal of Psychiatry 1995;152:1724-1729.
18. Choe MG, Hsuan F, Honigfeld G, Robinson WT, Ereshefsky L, Crismon ML, Saklad SR, Hirschowitz J, Wagner R. Single- vs multiple-dose pharmacokinetics of clozapine in psychiatric patients. Pharmacology Research 1990;7:347-351.
19. Cole JO, Goldberg SC, Klerman GL. Phenothiazine treatment in acute schizophrenia. Archives of General Psychiatry 1964;10:246-261.
20. Farde L, Nordstrom A-L, Wiesel F-A, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Archives of General Psychiatry 1992;49:538-544.
21. Gerlach J, Peacock L. New antipsychotics: the present status. International Clinical Psychopharmacology 1995;10 (Suppl. 3):39-48.
22. Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Archives of General Psychiatry 1995;52:173-188.
23. Gutierrez R, Lee PI, Huang ML, Woestenborghs R. Risperidone: effects of formulations on oral bioavailability. Pharmacotherapy 1997;17:599-605.
24. Harvey PD, Keefe RSE. Cognitive impairment in schizophrenia and implications of atypical neuroleptic treatment. CNS Spectrums 1997;2:41-55.
25. Heykants J, Huang M-L, Mannens G, Meuldermans W, Snoeck E, Van Beijsterveldt L, Van Peer A, Woestenborghs R. The pharmacokinetics of risperidone in humans: a summary. Journal of Clinical Psychiatry 1994;55 (Suppl.):13-17.
26. Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clinical Pharmacology and Therapeutics 1993;54:257-268.
27. Hyttel J, Arnt J, Costall B, Domeney A, Dragsted N, Lembol HL, Meier E, Naylor RJ, Nowak G, Sanchez C, et al. Pharmacological profile of the atypical neuroleptic sertindole. Clinical Neuropharmacology 1992;15 (Suppl. 1, Pt. A):267A-268A.
28. Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. Journal of Pharmacy and Experimental Therapeutics 1988;244:685-693.
29. Jibson MD, Tandon R. The negative symptoms of schizophrenia. Directions in Psychiatry 1995;15:1-7.
30. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988;45:789-796.
31. Kassahun K, Mattiuz E, Nyhart Jr. E, Obermeyer B, Gillespie T, Murphy A, Goodwin RM, Tupper D, Callaghan JT, Lemberger L. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metabolism and Disposition 1997;25:81-93.
32. Kleinberg DL, Brecher M, Davis JM. Prolactin levels and adverse events in patients treated with risperidone. Scientific Abstracts. 150th annual meeting of the American Psychiatric Association, May 17-22, San Diego, California, 1997.
33. Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. Journal of Clinical Psychiatry 1994;55 (Suppl. B):82-87.
34. Leysen JE, Gommeren W, Eens A, de Chaffoy de courcelles D, Stoof JC, Janssen PAJ. Biochemical profile of risperidone, a new antipsychotic. Journal of Pharmacology and Experimental Therapeutics 1988;247:661-670.
35. Lieberman J, Johns C, Cooper T, Pollack S, Kane J. Clozapine pharmacology and tardive dyskinesia. Psychopharmacology (Berl) 1989;99 (Suppl.):S54-S59.
36. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. American Journal of Psychiatry 1994;151:825-835.
37. Marder SR, Asarnow RF, Mintz J. Information processing and neuroleptic response in acute and stabilized schizophrenic patients. Psychiatry Research 1984;13:41-49.
38. McGurk SR, Green MF, Wirshing WC, Ames D, Marshall BD, Marder SR, Mintz J. The effects of risperidone vs haloperidol on cognitive functioning in treatment-resistant schizophrenia: the trail making test. CNS Spectrums 1997;2:60-64.
39. Medalia A, Gold J, Merriam A. The effects of neuroleptics on neuropsychological test results of schizophrenics. Archives of Clinical Neuropsychology 1988;3:249-271.
40. Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin 2 and dopamine 2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacology Bulletin 1989;25:390-392.
41. Meltzer HY, Casey DE, Garver DL, Lasagna L, Marder SR, Masand P, Miller D, Pickar D and Tandon R. Assessing the negative symptom data on atypical antipsychotics. Journal of Clinical Psychiatry. 1998, 59 (Suppl.), in press.
42. Miceli J, Hunt T, Cole MJ, et al. Clinical Pharmacology and Therapeutics 1994;55:142.
43. Miller DD and Tandon R. The Biology and Pathophysiology of Negative Symptoms, 1998. In press.
44. Milner K, Tomori O, Florence T, and Tandon R. Psychotropic medications and sexual dysfunction. In: Buckley PF, editor. Sexuality among patients with serious mental illness, American Psychological Association Press, 1998. In press.
45. Moller H-J, Muller H, Borison RL, Schooler NR, Chouninard G. A path-analytic approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. European Archives of Psychiatry and Clinical Neuroscience 1995;245:45-49.
46. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia; a multinational, multicentre, double-blind, parallel-group study versus haloperidol. British Journal of Psychiatry 1995;166:712-726.
47. Prakash C, Kamel A, Gummerus J, Wilner K. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metabolism and Disposition 1997;25:863-872.
48. Preskorn SH, Magnus RD. Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo findings and their implications for patient care. Psychopharmacology Bulletin 1994;30:251-259.
49. Richelson E. Pharmacology of neuroleptics in use in the United States. Journal of Clinical Psychiatry 1985;46:8-14.
50. Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. British Journal of Clinical Pharmacology 1996;41:181-186.
51. Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 1993;112:285-292.
52. Saykin AJ, Gur RC, Gur RE, Mozley PD, Mozley LH, Resnick SM, Kester DB, Stafiniak P. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Archives of General Psychiatry 1991;48:618-624.
53. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe 3rd. JA, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Journal of Pharmacy and Experimental Therapeutics 1995;275:101-113.
54. Serper MR, Chou JCY. Novel antipsychotics improve attentional functioning in schizophrenic patients: ziprasidone and aripiprazole. CNS Spectrums 1997;2:56-59.
55. Skarsfeldt T, Perregaard J. Sertindole, a new neuroleptic with extreme selectivity on A10 versus A9 dopamine neurones in the rat. European Journal of Pharmacology 1990;182:613-614.
56. Seroquel Study Group, Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CGG. Quetiapine in patients with schizophrenia. Archives of General Psychiatry 1997;54:549-557.
57. Spohn HE, Strauss ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. Journal of Abnormal Psychology 1989;98:367-380.
58. Strauss ME, Reynolds KS, Jayaram G, Tune LE. Effects of anticholinergic medication on memory in schizophrenia. Schizophrenia Research 1990;3:127-129.
59. Sweeney JA, Haas GL, Keilp JG, Long M. Evaluation of the stability of neuropsychological functioning after acute episodes of schizophrenia: one-year follow-up study. Psychiatry Research 1991;38:63-76.
60. Tamminga CA, Mack RJ, Granneman GR, Silber CJ, Kashkin KB. Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. International Clinical Psychopharmacology 1997;12 (Suppl. 1):S29-S35.
61. Tandon R. Antipsychotic agents. In: Klein DF and Rowland LP, editors. Current psychotherapeutic drugs. New York: Brunner/Mazel Publishers, 1998a. pp. 120-154.
62. Tandon R. Cholinergic aspects of schizophrenia. British Journal of Psychiatry 1998b. In press.
63. Tandon R, Kane JM. Neuropharmacological basis of clozapine's unique profile. Archives of General Psychiatry 1993;50:157-159.
64. Tandon R, Goldman R, DeQuardo JR, Goldman M, Perez M, Jibson M. Positive and negative symptoms covary during clozapine treatment in schizophrenia. Journal of Psychiatry Research 1993;27:341-347.
65. Tandon R, Jibson MD, Taylor SF, and DeQuardo JR. Conceptual models of the relationship between positive and negative symptoms. In: Shriqui CL and Nasrallah HA, editors. Contemporary issues in the treatment of schizophrenia. Washington, D.C.: American Psychiatric Press Inc., 1995, pp. 109-124.
66. Tandon R, Harrington E, Zorn SH. Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. Journal of Serotonin Research 1997;4:159-177.
67. Tandon R, DeQuardo JR and Taylor SF Neurobiology of Schizophrenia. In: Ananth J, editor. Textbook of psychopathology. New Delhi: Jaypee Brothers, 1998.
68. Thyrum PT, Fabre LF, Wong J, Ewing BJ, Yeh C. Multiple-dose pharmacokinetics of ICI 204,636 in schizophrenic men and women. Psychopharmacology Bulletin 1996;32:525.
69. Tollefson GD, Sanger TM. Negative Symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. American Journal of Psychiatry 1997;154:466-474.
70. Tollefson GD, Beasley Jr. CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry 1997;154:457-465.
71. Tollefson GD, Beasley Jr. CM, Tamura RN, Tran PV, Potvin JH. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. American Journal of Psychiatry 1997;154:1248-1254.
72. Tran PV, Dellva MA, Tollefson GD, Beasley Jr. CM, Potvin JH, Kiesler GM. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. Journal Clinical Psychiatry 1997;58:205-211.
73. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley Jr. C, Tollefson GD. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology 1997;17:407-418.
74. Tune LE, Strauss ME, Lew MF, Breitlinger E, Coyle JT. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. American Journal of Psychiatry 1982;139:1460-1462.
75. van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, Sebree TB. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl) 1996;124:168-175.
76. Van Putten T, Marder SR, Mintz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Archives of General Psychiatry 1990;47:754-758.
77. Wong SL, Linnen P, Mack R, Granneman GR. Effects of food, antacid, and dosage form on the pharmacokinetics and relative bioavailability of sertindole in healthy volunteers. Biopharmaceutics and Drug Disposition 1997;18:533-541.
78. Wong SL, Menacherry S, Mulford D, Schmitz PJ, Locke C, Granneman GR. Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function. European Journal of Pharmacology 1997;52:223-227.
79. Zeng XP, Le F, Richelson E. Muscarinic m4 receptor activation by some atypical antipsychotic drugs. European Journal of Pharmacology 1997;321:349-354.
80. Sertindole Study Group, Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Wallin BA, Kashkin KB. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. American Journal of Psychiatry 1997;154:782-791.